OpenFederal grantOpen to for-profit businessesPAR-25-070

Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)

National Institutes of HealthCloses Jan 7, 2027(86 days left)

Does this fit your business?

This is an NIH exploratory research grant (R21) for studies on how GLP-1 and GIP drugs affect cancer risk, not for weight loss or diabetes outcomes. It suits research-driven organizations with scientific staff; retail, finance, logistics, and other businesses with no research capability should not bother applying. Clinical trials are not allowed, and the award amount is not published.

Best for
Universities and academic research labs, Nonprofits and research institutes, Small biotech and for-profit research firms, State, local, and tribal government research programs
Not for
Businesses without research capability, Organizations seeking funding for clinical trials or service delivery
Estimated fit by industry, best first
IndustryEstimated fit
Healthcare & BiotechMatches your industry (clinical)
67
Good Match
Energy & Clean TechLimit: Nothing in this notice points to energy & clean tech
54
Possible Match
Environment & ConservationLimit: Nothing in this notice points to environment & conservation
54
Possible Match
Technology & SoftwareLimit: Nothing in this notice points to technology & software
54
Possible Match
Education & TrainingLimit: Nothing in this notice points to education & training
53
Possible Match
Arts & CultureLimit: Nothing in this notice points to arts & culture
51
Possible Match
Show all 15 industries
Estimated fit by industry, best first
IndustryEstimated fit
Food & BeverageLimit: Nothing in this notice points to food & beverage
51
Possible Match
Housing & Real EstateLimit: Nothing in this notice points to housing & real estate
50
Possible Match
Social Services & NonprofitLimit: Nothing in this notice points to social services & nonprofit
50
Possible Match
Agriculture & FarmingLimit: Nothing in this notice points to agriculture & farming
49
Possible Match
Construction & InfrastructureLimit: Nothing in this notice points to construction & infrastructure
49
Possible Match
Finance & BankingLimit: Nothing in this notice points to finance & banking
49
Possible Match
ManufacturingLimit: Nothing in this notice points to manufacturing
49
Possible Match
Retail & E-CommerceLimit: Nothing in this notice points to retail & e-commerce
49
Possible Match
Transportation & LogisticsLimit: Nothing in this notice points to transportation & logistics
49
Possible Match

These are our matcher’s estimates for a typical business in each industry. A real match depends on your size, your state and what you need the money for — check your own fit.

What this funds

Money can be used for
Research
Who can apply
Small businesses, For-profit companies, Nonprofits, State and local governments, Tribal governments and organizations, Colleges and universities, Other applicants (see eligibility)

Questions about this grant

When is the application deadline?
January 7, 2027.
Who can apply for this grant?
Universities, nonprofits, small businesses, for-profit organizations, state and local governments, federally recognized tribes, and certain other entities including foreign organizations, faith-based organizations, and minority-serving institutions. Clinical trials are not allowed under this award.
Can a sole proprietor or single-member LLC apply?
The facts do not say. Small businesses are listed as eligible, but there is no published guidance on sole proprietors or single-member LLCs specifically.
Can a nonprofit apply?
Yes. Both 501(c)(3) nonprofits and nonprofits without 501(c)(3) status are eligible.

Summary

NIH R21 grants for exploratory preclinical and patient-based research on how incretin mimetics (GLP-1/GIP agents) affect cancer risk. Eligible applicants include universities, nonprofits, small businesses, for-profit organizations, state/local/tribal governments, and some foreign entities; clinical trials not allowed.

About this grant

The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.

Who can apply

Other Eligible Applicants include the following:

Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Topics and uses of funds

Topics

  • Health
  • Science

Program contact

National Institutes of Healthgrantsinfo@nih.gov301-402-2541

Related grants

Open opportunities funding similar work, from the same funder or in the same place.

All grantsGrants by stateGrants by industry